[go: up one dir, main page]

PE20011113A1 - Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina - Google Patents

Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina

Info

Publication number
PE20011113A1
PE20011113A1 PE2001000206A PE2001000206A PE20011113A1 PE 20011113 A1 PE20011113 A1 PE 20011113A1 PE 2001000206 A PE2001000206 A PE 2001000206A PE 2001000206 A PE2001000206 A PE 2001000206A PE 20011113 A1 PE20011113 A1 PE 20011113A1
Authority
PE
Peru
Prior art keywords
formulation
agent
less
weight
ciprofloxacine
Prior art date
Application number
PE2001000206A
Other languages
English (en)
Inventor
Brij Khera
Gour Mukherji
Badri N Vishwanathan
John N Staniforth
Naresh Talwar
Ashok Rampal
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of PE20011113A1 publication Critical patent/PE20011113A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE LIBERACION CONTROLADA QUE COMPRENDE: a) UNA CANTIDAD EFECTIVA DE CIPROFLOXACINA; b) DE 0,1% A 8 % DE UN AGENTE DE VISCOSIDAD TAL COMO GOMA, ETERES DE CELULOSA DE PREFERENCIA GOMA XANTANO E HIDROXIPROPILCELULOSA Y/O UN AGENTE DE GELACION TAL COMO ALGINATO DE SODIO; c) DE 5% A 15% DE UNA AGENTE GENERADOR DE GAS TAL COMO BICARBONATO DE SODIO, CARBONATO DE CALCIO, CARBONATO DE SODIO Y; d) DE 3% A 15% DE UN AGENTE DE EXPANSION TAL COMO POLIVINILPIRROLIDONA , SIENDO TALES PORCENTAJES CON RELACION AL PESO/PESO DEL COMPUESTO. LA CIPROFLOXACINA SE LIBERA MAS DEL 50% DEL MEDICAMENTO EN MENOS DE 4 HORAS Y MAS DEL 60% DEL MEDICAMENTO EN MENOS DE 8 HORAS. LA FORMULACION COMPRENDE DE 100mg A 1000mg DE CIPROFLOXACINA Y EXCIPIENTES EN LA QUE EL PESO TOTAL DE LA FORMULACION CORRESPONDE A MENOS DE 2000mg. LA FORMULACION ES ADMINISTRADA VIA ORAL Y LA LIBERACION CONTROLADA DE CIPROFLOXACIONA SE PRODUCE EN EL ESTOMAGO O PARTE SUPERIOR DEL INTESTINO
PE2001000206A 2000-03-03 2001-03-01 Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina PE20011113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51788700A 2000-03-03 2000-03-03

Publications (1)

Publication Number Publication Date
PE20011113A1 true PE20011113A1 (es) 2001-10-14

Family

ID=24061635

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000206A PE20011113A1 (es) 2000-03-03 2001-03-01 Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina

Country Status (31)

Country Link
EP (1) EP1263409A1 (es)
JP (1) JP2003525229A (es)
KR (1) KR20030009374A (es)
CN (1) CN1420763A (es)
AP (2) AP2001002084A0 (es)
AR (1) AR032614A1 (es)
AU (1) AU3589701A (es)
BG (1) BG107055A (es)
BR (1) BR0108958A (es)
CA (1) CA2400950A1 (es)
CZ (1) CZ20022883A3 (es)
DO (1) DOP2001000130A (es)
EA (1) EA200200914A1 (es)
EC (1) ECSP013952A (es)
EE (1) EE200200497A (es)
GT (1) GT200100033A (es)
HN (1) HN2001000038A (es)
HR (1) HRP20020715A2 (es)
HU (1) HUP0204417A3 (es)
IL (1) IL151553A0 (es)
IS (1) IS6532A (es)
MX (1) MXPA02008568A (es)
NO (1) NO20024108L (es)
NZ (1) NZ520927A (es)
OA (1) OA12381A (es)
PE (1) PE20011113A1 (es)
PL (1) PL365071A1 (es)
SK (1) SK12542002A3 (es)
WO (1) WO2001064183A1 (es)
YU (1) YU66202A (es)
ZA (1) ZA200206764B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10351448A1 (de) 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
ATE396710T1 (de) * 2005-07-19 2008-06-15 Ethypharm Sa Gastroretentive zusammensetzungen und verfahren zur herstellung
EP1880722B1 (en) * 2006-07-19 2010-03-17 Tabuk Pharmaceutical Manufacturing Co. Pharmaceutical compositions of ciprofloxacin
WO2016115253A1 (en) 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
US20190070299A1 (en) * 2016-02-23 2019-03-07 Matripharm International Inc. Dual-rate release formulation with high drug loading
US9820957B2 (en) 2016-03-24 2017-11-21 The Regents Of The University Of Colorado, A Body Corporate Methods of treating autoimmunity
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN109806237A (zh) * 2019-03-13 2019-05-28 悦康药业集团上海制药有限公司 一种乳酸环丙沙星泡腾片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE19839057A1 (de) * 1998-08-28 2000-03-02 Koch Berthold Spülluft-Regler für eine Trockenvorrichtung für Druckluft
EA005767B1 (ru) * 1998-09-14 2005-06-30 Рэнбакси Лабораториз Лимитед Перорально вводимая система контролируемой доставки лекарственного средства, обеспечивающая временной и пространственный контроль

Also Published As

Publication number Publication date
CZ20022883A3 (cs) 2003-04-16
HN2001000038A (es) 2005-03-23
HUP0204417A3 (en) 2005-03-29
CN1420763A (zh) 2003-05-28
NO20024108L (no) 2002-10-25
DOP2001000130A (es) 2004-03-31
EE200200497A (et) 2004-02-16
ECSP013952A (es) 2002-04-23
EA200200914A1 (ru) 2003-02-27
CA2400950A1 (en) 2001-09-07
PL365071A1 (en) 2004-12-27
AP1485A (en) 2005-10-31
JP2003525229A (ja) 2003-08-26
MXPA02008568A (es) 2003-02-24
ZA200206764B (en) 2003-03-04
NZ520927A (en) 2003-06-30
KR20030009374A (ko) 2003-01-29
AP2001002084A0 (en) 2001-03-31
EP1263409A1 (en) 2002-12-11
HRP20020715A2 (en) 2004-12-31
WO2001064183A1 (en) 2001-09-07
SK12542002A3 (sk) 2003-05-02
AR032614A1 (es) 2003-11-19
NO20024108D0 (no) 2002-08-28
AU3589701A (en) 2001-09-12
GT200100033A (es) 2001-10-25
HUP0204417A2 (en) 2003-05-28
BG107055A (bg) 2003-06-30
YU66202A (sh) 2005-09-19
IS6532A (is) 2002-08-28
OA12381A (en) 2004-09-06
BR0108958A (pt) 2003-09-30
AP2002002627A0 (en) 2002-09-30
IL151553A0 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
AR022672A1 (es) Una composicion farmaceutica en forma de tabletas o capsulas que constituyen un metodo de administracion oral de una droga
ES2251494T3 (es) Formulacion de accion rapida.
SI1898876T1 (sl) MUKOADHEZIVNE FARMACEVTSKE OBLIKE, KI VSEBUJEJO KSILOGlUKAN IN SO UPORABNE V MEDICINSKIH SREDSTVIH IN APLIKACIJSKIH OBLIKAH
YU19501A (sh) Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu
BR0113626A (pt) Formulações de liberação sustentada para secretores de hormÈnio do crescimento
PE20011113A1 (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
AR041370A1 (es) Formulaciones farmaceuticas solidas que comprenden telmisartano y su preparacion
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
NZ511900A (en) Sustained release matrix systems for highly soluble drugs
BR0312640A (pt) Formulação contra mycoplasma gallisepticum
ES2113136T3 (es) Composiciones farmaceuticas de gemfibrozil y procedimiento para su preparacion.
MX9704043A (es) Surtido de farmaco de liberacion sostenida empleando una goma de hidrocoloide en polvo obtenible a partir de plantas superiores.
UY26176A1 (es) Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas.
ES2238497T3 (es) Granulado de ribavirina para la obtencion de comprimidos peliculados.
BR0318167A (pt) formulação de liberação controlada contendo um material hidrofóbico como o agente de liberação controlada
UY26605A1 (es) Sistema de administración oral controlada para la ingestión diaria de ciprofloxacina
MD2975F1 (en) Remedy in the form of gel for rosacea treatment
MD2976F1 (en) Remedy in the form of gel for acnea treatment
SV2003000335A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
BR0300434A (pt) Composição farmacêutica oral, utilizada como antiespasmódico geral do músculo liso com aplicações biliares, digestivas, urinárias e ginecológicas, e no tratamento da cólica intestinal moderada a severa, e, uso da mesma
LT2006062A (lt) Elementinės sieros vaistiniai produktai, skirti su glutationo s transferazės fermentu susijusioms ligoms gydyti
GT199800053A (es) Composiciones farmaceuticas paraadministracionoraldeln-piperidino-5-(4-clorofenil)-1-(2,4-diclorofenil)-4-metilpirazolo-3-carboxamida, de sus salesy desussolvatos.

Legal Events

Date Code Title Description
FC Refusal